Proton Pump Inhibitor–Associated Hypomagnesemia: What Do FDA Data Tell Us?

Abstract

Spanish

French

BACKGROUND:

Proton pump inhibitors (PPIs) are a class of medications indicated for the treatment of gastric acid–related diseases. Hypomagnesemia is a rare but serious adverse effect of PPIs.

OBJECTIVE:

To address the association between the use of different PPIs and hypomagnesemia by examining the frequency of occurrence of hypomagnesemia among the reported adverse drug reactions from the Food and Drug Administration (FDA) Adverse Event Reporting System database.

METHODS:

We conducted a cross-sectional study of PPI-associated adverse effect cases reported to the FDA between November 1, 1997, and April 1, 2012. Logistic regression was used to examine the association of sex, age, and different PPIs with hypomagnesemia. χ² Analysis was conducted to investigate the association of PPI-associated hypomagnesemia with hypocalcemia and hypokalemia.

RESULTS:

Among 66,102 subjects identified as experiencing 1 or more adverse effects while taking a PPI, 1.0% (n = 693) were reported to have hypomagnesemia. The mean (SD) age of PPI users presenting with hypomagnesemia was 64.4 (12.9) years. Results from logistic regression indicated that, compared with esomeprazole, all other PPIs had a higher rate of hypomagnesemia, with pantoprazole having the highest rate (OR 4.3; 95% CI 3.3–5.7; p < 0.001). The risk of female subjects having hypomagnesemia (OR 0.83; 95% CI 0.71–0.97; p = 0.016) was significantly lower than that of males. Elderly subjects (age >65 years) were at increased risk of PPI-associated hypomagnesemia (OR 1.5; 95% CI 1.2–1.7; p < 0.001). χ² Analysis showed strong association between hypomagnesemia and both hypocalcemia (p < 0.001) and hypokalemia (p < 0.001).

CONCLUSIONS:

All PPIs were associated with hypomagnesemia, with esomeprazole having the lowest risk and pantoprazole having the highest risk. The risk of PPI-associated hypomagnesemia was higher in males and the elderly population. Hypocalcemia and hypokalemia commonly coexisted with PPI-associated hypomagnesemia.

Get full access to this article

View all access options for this article.

References

Shi

, Klotz

. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935–51.

Savarino

, Di Mario

, Scarpignato

. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59: 135–53.

Mullin

, Gabello

, Murray

, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009; 14: 647–60.

Ito

, Jensen

. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B₁₂, iron, and magnesium. Curr Gastroenterol Rep 2010; 12: 448–57.

Commonwealth Government of Australia. Drug Utilisation Subcommittee (DUSc) database. www.australianprescriber.com/magazine/34/6/artid/1063 (accessed 2012 Apr 9).

Lodato

, Azzaroli

, Turco

, et al. Adverse effects of proton pump inhibitors. Baillieres Best Pract Res Clin Gastroenterol 2010; 24: 193–201.

Sheen

, Triadafilopoulos

. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 931–50.

Vakil

. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012; 72: 437–45.

Yang

, Metz

. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115–27.

10.

Cundy

, Mackay

. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011; 27: 180–5.

11.

Epstein

, McGrath

, Law

. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834–6.

12.

Shabajee

, Lamb

, Sturgess

, Sumathipala

. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.

13.

Cundy

, Dissanayake

. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008; 69: 338–41.

14.

Francois

, Levy-Bohbot

, Caron

, Durlach

. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? [French] Annales d Endocrinologie 2008; 69: 446–8.

15.

Agarwal

, Rees

, Scanlon

. Hypomagnesaemia related to proton-pump inhibition. Endocrine Abstracts 2008; 15: P24.

16.

Broeren

MAC

, Geerdink

EAM

, Vader

, van den Wall Bake

AWL

. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151: 755–6. [Erratum appears in Ann Intern Med 2010; 152:268].

17.

Kuipers

, Thang

, Arntzenius

. Hypomagnesaemia due to use of proton pump inhibitors—a review. Neth J Med 2009; 67: 169–72.

18.

Druce

, Thomas

JDJ

, Gorrifan

, Kelly

, Coppack

, Akker

. Hypomagnesaemia and hypocalcaemia in proton-pump inhibitors: an under-recognised phenomenon. Endocrine Abstracts 2009; 16: P50.

19.

Hoorn

, van der Hoek

, de Man

, Kuipers

, Bolwerk

, Zietse

. A case series of proton pump inhibitor–induced hypomagnesemia. Am J Kidney Dis 2010; 56: 112–6.

20.

Regolisti

, Cabassi

, Parenti

, Maggiore

, Fiaccadori

. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010; 56: 168–74.

21.

Mackay

, Bladon

. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010; 103: 387–95.

22.

Fernandez-Fernandez

, Sesma

, Cainzos-Romero

, Ferreira-Gonzalez

. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 2010; 68: 329–30.

23.

Swaminathan

, Wilson

. Elusive cause of hypomagnesaemia. BMJ 2011; 343: d5087.

24.

Arulanantham

, Anderson

, Gittoes

, Ferner

. A 63-year-old man with hypomagnesaemia and seizures. Clin Med 2011; 11: 591–3.

25.

Furlanetto

, Faulhaber

GAM

. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011; 171: 1391–2.

26.

Quasdorff

, Mertens

, Dinter

, Steffen

H-M

. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med 2011; 155: 405–7.

27.

Ayuk

, Gittoes

NJL

. How should hypomagnesaemia be investigated and treated? Clin Endocrinol 2011; 75: 743–6.

28.

Negri

, Valle

EED

. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Curr Drug Saf 2011; 6: 204–6.

29.

Cano Megías

, Álvarez Santirso

, Iglesias Lozano

, Carrasco De La Fuente

, Pérez López

. Hypomagnesemia induced by proton pump inhibitors, diarrhea, and lactose intolerance. Endocrinol Nutr 2011; 58: 550–4.

30.

Metz

, Sostek

, Ruszniewski

, Forsmark

, Monyak

, Pisegna

. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648–54.

31.

Hmu

, Moulik

, Macleod

. Severe hypomagnesaemia due to lansoprazole. BMJ Case Rep 2009. doi: 10.1136/bcr.07.2009.2098

32.

Matsuyama

, Tsuji

, Doyama

, et al. Hypomagnesemia associated with a proton pump inhibitor. Intern Med 2012; 51: 2231–4.

33.

Martinez Faedo

, Bellido Castaneda

, Riestra Fernandez

. [Severe hypomagnesemia refractory to oral supplementation associated to omeprazole treatment]. Endocrinol Nutr 2012; 59: 463–5.

34.

Chen

, Yuan

, Leontiadis

, Howden

. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46: 93–114.

35.

Sumukadas

, McMurdo

MET

, Habicht

. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am Geriatr Soc 2012; 60: 392–3.

36.

Gau

, Yang

, Chen

, Kao

. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012; 21: 553–9.

37.

Food and Drug Administration. FDA drug associated with long-term use of proton pump inhibitor drugs. www.fda/gov/Drugs/DrugSafety/ucm245011.htm (accessed 2012 Apr 9).

38.

Therapeutic Goods Administration. Medicines safety update. www.tga.gov.au/hp/msu-2011-03.htm (accessed 2012 Apr 9).

39.

Lameris

, Monnens

, Bindels

, Hoenderop

JGJ

. Drug-induced alterations in Mg2+ homoeostasis. Clin Sci (Colch) 2012; 123: 1–14.

40.

Miner

Jr , Katz

, Chen

, Sostek

. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616–20.

41.

Kroenke

, Spitzer

. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998; 60: 150–5.

42.

George

, Korc

, Ross

. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother 2008; 6: 249–54.

43.

, Carter

. Abnormal laboratory results. Magnesium: the forgotten electrolyte. Aust Prescr 2007; 30: 102–5.

44.

Gums

. Magnesium in cardiovascular and other disorders. Am J Health Syst Pharm 2004; 61: 1569–76.

45.

Maeda

, Kojima

, Araki

, Uno

, Nishigaki

, Inaba

. Does a proton pump inhibitor cause hypokalemia? Intern Med 2011; 50: 1045–50.

46.

Evenepoel

. Alteration in digestion and absorption of nutrients during profound acid suppression. Baillieres Best Pract Res Clin Gastroenterol 2001; 15: 539–51.

47.

Thongon

, Krishnamra

. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol 2011; 17: 1574–83.

48.

Mullin

, Valenzano

, Whitby

, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008; 28: 1317–25.